In ophthalmology, PMMA has been a staple for over 50 years, primarily as intraocular lenses (IOLs) to restore vision after cataract surgery. Its optical clarity, stability, and resistance to yellowing make it ideal for implants that need to last decades. But recent advancements are expanding PMMA’s role, from foldable IOLs for minimally invasive surgery to PMMA-based corneal implants and drug-eluting contact lenses for chronic eye conditions.

Traditional PMMA IOLs are rigid, requiring larger incisions, but new foldable formulations allow insertion through tiny 2mm cuts, reducing post-surgical discomfort and healing time. Researchers are also exploring PMMA composites with UV-blocking properties to protect the retina from harmful radiation, a feature increasingly demanded by patients in regions with high sun exposure. Additionally, PMMA is being tested in drug-eluting lenses that release anti-inflammatory or antibiotic agents locally, reducing the need for post-op eye drops.

The ophthalmology PMMA market advancements report details how these innovations are boosting demand. It notes that foldable PMMA IOLs now account for 35% of global IOL sales, up from 15% in 2018, driven by their popularity among surgeons. The report also highlights emerging markets like Brazil and Nigeria, where cataract surgery rates are rising, creating new opportunities for PMMA IOL manufacturers.

Competition, however, is fierce. Silicone and hydrogel IOLs, with better flexibility and lower inflammation risk, are gaining market share. To stay competitive, PMMA manufacturers are focusing on precision engineering—producing thinner, lighter lenses—and enhancing material properties. Regulatory hurdles, such as proving long-term safety for drug-eluting variants, also require significant investment. Yet PMMA’s stability and cost-effectiveness ensure it remains a preferred choice, particularly in resource-limited settings, securing its future in ophthalmology.